Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
Latest news on NOVARTIS AG
11/02 NOVARTIS AG (NYSE : NVS) And Pfizer Inc. (NYSE:PFE) Are In A Race To Gain Favor ..
11/02 NOVARTIS : Wins Two Prestigious Prix Galien Foundation Awards
11/01 Pfizer cholesterol drug fizzles, hitting shares
11/01 NOVARTIS : Wins Two Prestigious Prix Galien Foundation Awards; Gleevec recognize..
11/01 NOVARTIS : Astex Achieves Milestone on US FDA Filing of New Drug Application for..
11/01 INCYTE : posts solid earnings performance in third quarter
11/01 NOVARTIS : LEE011 (ribociclib) granted FDA Priority Review for first-line treatm..
10/31 NOVARTIS : Teva tries to delay generic double dose Copaxone
10/31 NOVARTIS : Wins Two Prestigious Prix Galien Foundation Awards; Gleevec® recogniz..
10/30 NOVARTIS : Teva attempts to delay generic double dose Copaxone
10/28 EXCLUSIVE - GERMANY'S MERCK EXPLORES : sources
10/28 NOVARTIS : Change at the helm of
10/26 MEDICINES COMPANY (NASDAQ : MDCO) Files An 8-K Reports Third-Quarter 2016 Financ..
10/25 NOVARTIS AG (NYSE : NVS), To Halt Unloading Roche Holding Stake?
10/25 NOVARTIS : beats 3Q profit forecasts
10/25DJStocks Fall on Mixed Earnings Reports
10/25 NOVARTIS : profit slips as key drug goes generic
10/25DJNOVARTIS : Profit Helped by GlaxoSmithKline Joint Venture -- Update
10/25 NOVARTIS : delivered solid third quarter with Growth Products offsetting Gleevec..
10/24 GLOBAL CLOZAPINE MARKET 2016 : Novartis, Cambrex, Arevipharma, Medichem, Shougua..
10/20 NOVARTIS : Researchers Submit Patent Application, "2'-Branched Nucleosides for T..
10/20 NOVARTIS : breakthrough therapy LEE011 ribociclib plus letrozole demonstrates su..
10/20 NOVARTIS : The American Heart Association and Novartis Shine a Light on America'..
10/20 Positive Phase III Clinical Trial Results for Ribociclib (LEE011), an Investi..
10/20 CERULEAN PHARMA INC. (NASDAQ : CERU) Files An 8-K
10/19 CERULEAN PHARMA : CERU) Higher on $20M Purchase Agreement with Aspire Capital, A..
10/19 NOVARTIS : Kala azar the bane of West Pokot  
10/19 NOVARTIS : Cerestra buys alexandria r&d park
10/18 NOVARTIS : Alcon launches the CyPass Micro-Stent at the American Academy of Opht..
10/18 Pfizer to start shipping biosimilar version of J&J's Remicade in November
10/17 NOVARTIS : Alcon launches the CyPass® Micro-Stent at the American Academy of Oph..
10/17DJPfizer Plans to Launch Remicade Biosimilar in November
10/17 Pfizer to launch cheaper version of J&J immune drug Remicade
10/15 COHERENT : APUC Limited awarded contract for Femtosecond Lasers
10/13 NOVARTIS : Patent Issued for Valve Position Detection (USPTO 9456924)
10/13 NOVARTIS AG (NYSE : NVS) Unveils Positive ASCEND-3, ASCEND-5 Results
10/10 NOVARTIS : Global Inhalation & Nasal Spray Generic Drugs Market 2016 - Mylan, Ho..
10/10 NOVARTIS' : Tafinlar (dabrafenib) + Mekinist (trametinib) demonstrate superior o..
10/09 NOVARTIS : ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survi..
10/09 NOVARTIS : ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survi..
10/08 NOVARTIS' : Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrate superior..
10/08 NOVARTIS : ' Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrate superio..
10/08 NOVARTIS : breakthrough therapy LEE011 plus letrozole demonstrates superior prog..
10/08 NOVARTIS : breakthrough therapy LEE011 plus letrozole demonstrates superior prog..
10/07 NOVARTIS : Alcon Research Assigned Patent
10/06 NOVARTIS : Patent Issued for Respirable Agglomerates of Porous Carrier Particles..
10/06 NOVARTIS : receives three new FDA approvals for the expanded use of Ilaris for p..
10/06 MERCK & CO., INC. (NYSE : MRK) Shuts Down Florida Facility
10/06 NOVARTIS AG (NYSE : NVS) Relocates NITD To California
10/05DJEli Lilly to Buy Boehringer Ingelheim Pet Vaccines Portfolio
10/05 NOVARTIS : Alcon Lensx Assigned Patent
10/04 NOVARTIS : Researchers identify a key molecule in psoriasis development
10/04 NOVARTIS AG (NYSE : NVS) Presents Encouraging Cosentyx Data
10/03 NOVARTIS : late-breaking data show Cosentyx delivers high and long-lasting skin ..
10/03 NOVARTIS : reports over half of psoriasis patients do not reach the achievable t..
10/03DJNovo Nordisk Bets on Riskier Insulin Research
10/01 NOVARTIS : $667,100 Federal Contract Awarded to Alcon Laboratories
10/01 NOVARTIS : late-breaking data show Cosentyx delivers high and long-lasting skin ..
10/01 NOVARTIS : late-breaking data show Cosentyx delivers high and long-lasting skin ..
09/30 GlaxoSmithKline to pay $20 million to settle U.S. foreign bribery case
09/30 GSK names new head of Consumer Healthcare division
09/30 NOVARTIS : MILITARY $130,430 Federal Contract Awarded to Alcon Laboratories
09/29 NOVARTIS : Patent Issued for Pharmaceutical Combinations (USPTO 9446043)
09/29 CHARTER COMMUNICATIONS : Names Rhonda Crichlow Chief Diversity Officer
09/28 NOVARTIS : Global Metoprolol Tartrate Market 2016- Novartis, AstraZeneca, Teva, ..
09/28 NOVARTIS : announces Phase III study shows AMG 334 significantly reduces monthly..
09/28 GLOBAL DRUGS FOR TREATMENT OF MULTIP : Janssen, Celgene, Bristol-Myers Squibb, G..
09/28 NOVARTIS : Sandoz invites young entrepreneurs to enter Sandoz HACk, a global com..
09/27 XENCOR : grows in San Diego
09/26 NOVARTIS : receives three new FDA approvals for the expanded use of Ilaris treat..
09/26 NOVARTIS : announces positive top-line results from ASCEND-4, a Phase III trial ..
09/26 NOVARTIS : Nouscom Appoints New Chief Operating Officer and Strengthens the Boar..
09/23 NOVARTIS : receives three new FDA approvals for the expanded use of Ilaris treat..
09/23 NOVARTIS : Alcon Research Assigned Patent
09/23 NOVARTIS : announces positive top-line results from ASCEND-4, a Phase III trial ..
Prev.1   2  3  4  5  6  7  8  9  10Next
Advertisement
Financials ($)
Sales 2016 48 805 M
EBIT 2016 11 856 M
Net income 2016 7 810 M
Debt 2016 15 084 M
Yield 2016 4,16%
P/E ratio 2016 19,70
P/E ratio 2017 18,53
EV / Sales 2016 3,97x
EV / Sales 2017 3,89x
Capitalization 178 737 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 83,3 $
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-19.07%178 737
JOHNSON & JOHNSON9.00%304 591
PFIZER INC.-2.01%191 942
ROCHE HOLDING LTD.-19.61%188 878
MERCK & CO., INC.15.85%168 544
SANOFI-4.20%103 510
More Results